

1 **TITLE**

2 Immunohistochemical expression of TFF1 is a new prognostic marker in retinoblastoma.

3

4 **RUNNING TITLE**

5 TFF1 as a prognostic marker in retinoblastoma.

6

7 **AUTHORS**

8 Rosario Aschero, PhD^{1,2,3,4}; Daiana Ganiewich, BEng⁵; Gabriela Lamas, MD¹; Camilo A Restrepo-
9 Perdomo, MD⁶; Daniela Ottaviani, Ph⁷; Santiago Zugbi, Bs^{2,8}; Sandra Camarero, AS¹; Ezequiel
10 Néspoli, AS¹; Maria Cuadrado Vilanova, PhD^{3,4}; Sara Perez-Jaume, PhD^{3,4}; Guillem Pascual-
11 Pasto, PhD^{3,4}; Claudia Sampor, MD⁹; Nathalia Grigorovski, MD¹⁰; Beatriz Salas, MD¹¹; ; Mariona
12 Suñol, MD⁶; Angel M. Carcaboso, PhD^{3,4}; Jaume Mora, MD, PhD^{3,4}; María T G de Dávila, MD,
13 PhD¹; François Doz MD⁷, François Radvanyi, PhD⁷; David H Abramson, MD¹²; Andrea S Llera,
14 PhD^{2,5,13}; Paula S Schaiquevich, PhD^{2,8}; Fabiana Lubieniecki, MD¹; Guillermo L Chantada, MD,
15 PhD^{2,3,4,14*}.

16

17 ***Address for correspondence:** Dr Guillermo L Chantada, Hospital Sant Joan de Déu. Pediatric
18 Cancer Center Barcelona, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Barcelona, Spain.
19 Email: guillermoluis.chantada@sjd.es

20

21 ¹ Pathology Service, Hospital de Pediatria JP Garrahan, Buenos Aires 1245, Argentina.

22 ² National Scientific and Technical Research Council, CONICET, Buenos Aires 1425, Argentina.

23 ³ SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, 08950, Spain.

24 ⁴ Institut de Recerca Sant Joan de Deu, Barcelona, 08950, Spain.

25 ⁵ Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires,
26 Argentina.

27 ⁶ Pathology Service, Hospital Sant Joan de Deu, Barcelona, 08950, Spain.

28 ⁷ SIREDO Center, Institut Curie and University Paris Cité, Paris, France

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 ⁸ Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires 1245,
31 Argentina.

32 ⁹ Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires 1245,
33 Argentina.

34 ¹⁰ Department of Pediatric Oncology, Clinical Division, National Institute of Cancer, Rio de
35 Janeiro, Brazil.

36 ¹¹ Hospital del Niño Manuel A. Villarroel, Cochabamba 2500, Bolivia.

37 ¹² Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, NY 10065, US.

38 ¹³ Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones
39 Bioquímicas de Buenos Aires (IIBBA), Buenos Aires 1405, Argentina.

40 ¹⁴ Hematology Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay.

41

42 **Address for reprints**

43 Guillermo L Chantada. SJD Pediatric Cancer Center Barcelona, Santa Rosa 39-57, 08950

44 Esplugues de Llobregat, Barcelona, Spain.

45 Email: guillermoluis.chantada@sjd.es

46

47 **PRÉCIS**

48 TFF1 expression is a prognostic marker of extraocular relapse and death in patients with
49 high-risk retinoblastoma.

50

51 **CONFLICT OF INTEREST**

52 The authors declare no conflict of interest.

53

54 **ACKNOWLEDGMENTS (FINANCIAL SUPPORT)**

55 This research was funded by the Agencia Nacional de Promoción Científica y Tecnológica
56 (Buenos Aires, Argentina) (PIDC 2014-0043); Fondation Nelia et Amadeo Barletta (Nyon,
57 Switzerland); Ligue Nationale Contre le Cancer and Rétinostop (Paris, France); Fundación Leo
58 Messi (Barcelona, Spain); Fund for Ophthalmic Knowledge (New York, United States of America)
59 Instituto Nacional del Cáncer (Buenos Aires, Argentina); Fundación Natali Dafne Flexer de Ayuda

60 al Niño con Cancer (Buenos Aires, Argentina); Fundación Garrahan (Buenos Aires, Argentina)
61 and Instituto Oncológico Henry Moore (Buenos Aires, Argentina).

62 The sponsors or funding organizations had no role in the design or conduct of this research.

63

64 **ABBREVIATIONS/ACRONYMS**

65 ARR3: Arrestin-C

66 CI: Confidence interval

67 CNA: Copy number alterations

68 CNS: Central nervous system

69 CRX: Cone-rod homeobox

70 EFS: Event-free survival

71 HPG: Hospital de Pediatría JP Garrahan

72 HR: Hazard ratio

73 HRPF: High-risk pathology factors

74 HS1: Histological subtype 1

75 HS2: Histological subtype 2

76 INCA: Instituto Nacional de Cáncer

77 IRSS: International retinoblastoma stage system

78 MSKCC: Memorial Sloan Kettering Cancer Center

79 OS: Overall survival

80 QS: Quick score

81 SJD: Hospital Sant Joan de Déu

82 TFF1: Trefoil factor 1

83

84

85

86

87

88

89

90 **ABSTRACT**

91 **Introduction:** The risk of relapse in retinoblastoma is currently determined by the presence of
92 high-risk histopathologic factors in the enucleated eye. However, the probability of developing
93 metastatic disease is heterogeneous among these patients. Evaluating a biological marker to
94 identify high-risk patients could be useful in clinical setting. This study aims to evaluate whether
95 the expression of TFF1, a surrogate for subtype 2 retinoblastoma, is a prognostic marker for
96 relapse and death.

97 **Methods:** This multicenter cohort study included 273 patients, 48 of whom had extraocular
98 disease. Immunohistochemical staining were performed for CRX, ARR3, TFF1 and Ki67. Tumors
99 were classified as histological subtype 1 (HS1) if they had low or no expression of TFF1 (quick
100 score (QS) ≤ 50) and as histological subtype 2 (HS2) if they expressed TFF1 diffusely (QS > 50).
101 We studied the association between HS classification and outcome.

102 **Results:** Of 273 patients, 35.9% were classified as HS1, 59.3% as HS2 and 4.8% were not
103 evaluable. In multivariate analysis, patients with HS2 tumors had a higher probability of relapse
104 and death than those with HS1 ($P < 0.0001$ and $P = 0.00020$, respectively). We identified a higher-
105 risk subgroup among HS2 tumors, presenting non-mutually exclusive expression of ARR3 and
106 TFF1 and had an increased risk of relapse and death compared to tumors that displayed mutually
107 exclusive expression ($P = 0.012$ and $P = 0.027$, respectively).

108 **Conclusions:** Expression of TFF1, especially when it is not-mutually exclusive with ARR3, is an
109 independent prognostic marker of poor outcome in retinoblastoma.

110

111 **KEY WORDS**

112 High-risk retinoblastoma; Prognostic marker; TFF1 expression; Histological subtypes

113

114

115

116

117

118

119

120 INTRODUCTION

121 Retinoblastoma is the most common pediatric ocular cancer and one of the index tumors
122 proposed by the World Health Organization for global action¹. Though highly curable in high
123 income countries, worldwide about 50% of affected children die from metastases².

124 Many patients need enucleation of the affected eye for treatment and the most important high-
125 risk histopathologic factors (HRPF) for extraocular relapse are invasion of choroid, optic nerve
126 and sclera³. Tumors without these features are very unlikely to develop extraocular disease, and
127 no further treatment after enucleation is recommended⁴. Although HRPF correlate with a greater
128 risk of metastases, most children whose tumors display these features will never develop
129 metastatic relapse^{5,6}. There is no clear consensus about who should receive adjuvant therapy to
130 reduce the risk of metastatic relapse since this risk is variable among the different groups⁶⁻⁸.
131 Furthermore, in addition to the presence of HRPF, there may be undefined biological features
132 that determine the risk of relapse.

133 Recently, two retinoblastoma biological subtypes have been described by multi-omic analysis.
134 Subtype 1 tumors express genes associated with late cone differentiation, have few genetic
135 alterations other than *RB1* inactivation. In contrast, subtype 2 tumors exhibit stemness features,
136 intratumoral heterogeneity expressing less differentiated cone and neuronal/ganglion cell markers
137 and nearly all harbor other genetic alterations⁹. Since metastatic dissemination was reported in
138 subtype 2 but not in subtype 1 tumors, it would be critical to identify subtype 2 tumors in clinical
139 settings mainly where multi-omic analysis are not widely available, like in countries with limited
140 resources where HRPF are more prevalent.

141 In subtype 2 tumors, gene expression analysis showed that the *Trefoil factor 1 (TFF1)*, is the top
142 up-regulated gene⁹. TFF1 is not expressed in the normal retina¹⁰ and has little or no expression
143 in subtype 1 tumors⁹. TFF1 antibodies are commercially available for immunohistochemistry, that
144 might be useful for identifying subtype 2 tumors in the clinical setting.

145 In the present study, we aimed to evaluate the expression of TFF1 by immunohistochemistry, as
146 histological surrogate for subtype 2 retinoblastoma and assess its potential role as a predictive
147 risk factor for metastatic relapse and survival in a large series of patients.

148

149 METHODS

150 **Patients**

151 We included an initial cohort of 252 consecutive patients with retinoblastoma stage 0-I with HRPF
152 and II-IV according to the International retinoblastoma staging system (IRSS)¹¹ from Hospital JP
153 Garrahan (HPG, Argentina) treated between 1988 and 2020 and all enucleated eyes regardless
154 of HRPF from Hospital Sant Joan de Déu (SJD, Spain) between 1983 and 2018.

155 The inclusion criteria were the availability of biological samples that were clinically annotated.
156 Exclusion criteria was the diagnosis of trilateral disease because the outcome is not dependent
157 on HRPF.

158 To increase the number of cases with extraocular disease, we included an expanded cohort of
159 patients with extraocular disease from other collaborating institutions. However, since these
160 patients were not consecutive, they were included only in immunohistochemistry descriptive
161 analysis and were excluded of all statistical analyses. Therefore, a total of 273 patients were
162 included in the study.

163

164 **Patient classification**

165 Patients were classified according to the IRSS (**Figure S1**). Patients from the initial cohort with
166 intraocular disease at diagnosis ($N = 242$) were either secondary enucleated after eye-
167 conservative treatment ($N = 28$), enucleated as first-line treatment ($N = 206$), or treated with
168 neoadjuvant therapy because of buphthalmos ($N = 5$)¹². In three cases, parents declined
169 enucleation when it was indicated, and these patients were later enucleated. Ten children
170 presented with extraocular disease at diagnosis, of whom nine received neoadjuvant therapy prior
171 to enucleation.

172 The expanded cohort ($N = 21$) included additional patients with disseminated retinoblastoma.
173 Fourteen patients had intraocular disease at diagnosis, five had extraocular retinoblastoma, and
174 two children developed extraocular disease due to enucleation refusal at diagnosis.

175

176 **Clinical and histopathological studies**

177 For each patient we retrieved clinical, treatment and survival data from each institutional
178 database. For the histological study, pathology slides were blindly reviewed by two independent

179 researchers and tumors were retrospectively assigned a pTNM stage¹³ when not recorded
180 prospectively.

181 Immunohistochemical staining was performed on 3 µm thick sections of paraffin-embedded
182 tissue, selecting, when available, the block with the central pupil-optic nerve section, ideally
183 containing the optic nerve, tumor and anterior chamber structures¹⁴. To characterize the
184 expression of photoreceptor-associated markers, we evaluated the cone-rod homeobox (CRX)
185 (ab140603; Abcam, Cambridge, UK), an early photoreceptor marker and arrestin-C (ARR3)
186 (11100-2-AP; Proteintech Group, Manchester, UK) as a marker of late cone differentiation.
187 Expression of TFF1 (HPA003425; Sigma-Aldrich Sigma, St. Louis, USA) was selected as a
188 surrogate marker for subtype 2 tumors. We also evaluated Ki67 expression in all cases to assess
189 the cell proliferation index (M7240, Agilent, Santa Clara, USA). We revealed the slides using
190 Novolink Polymer detection System (Leica Biosystems, Wetzlar, Germany).

191 Additional information about the conditions and positive controls used are described in **Table S1**.
192 To quantify the immunostaining results, the quick score (QS) was performed as reported
193 previously^{9,15}. Briefly, the intensity was classified as negative (0), mild (1), moderate (2) or strong
194 (3) and the percentage of positive cells at any intensity level was calculated. The QS was
195 calculated as $(Intensity_{highest}) * (Percentage_{total})$, and the result score from 0 to 300. QS value
196 reported is the mean of QS resulting from the assessment of two specialist. In case of
197 discrepancy, a third observer evaluated the slides and the case was classified by consensus.
198 Using previously reported criteria, we defined histological subtype 1 (HS1) tumors as those with
199 a TFF1 QS value ≤ 50 and histological subtype 2 (HS2) tumors as those with TFF1 QS value $>$
200 50^9 in enucleated eyes or metastatic sites when no ocular tissue was available. Patients with
201 bilateral disease enucleated from both eyes who presented a different subtype in each eye were
202 classified as HS2 (**Table S2**).

203

204 **Statistical analyses**

205 Statistical analyses were performed in R/RStudio v4.1.0. Comparisons of clinical and histological
206 features were performed using the Wilcoxon test for continuous variables and the Fisher's exact
207 test for categorical variables. A *P* value cut-off of 0.05 was used to assess statistical significance.
208 Event-free survival (EFS) and overall survival (OS) were defined as the time from diagnosis to

209 first event (relapse or death, respectively) or last follow-up. Kaplan-Meier¹⁶ plots and log-rank
210 test¹⁷ were used to compare the survival distributions (GraphPad Prism 8 Software, La Jolla, CA,
211 USA). Cox proportional hazards regression models¹⁸ with Firth correction¹⁹ were used to test
212 associated with outcome. Only variables statistically significant in the univariate analysis were
213 included in the multivariate analysis.

214 For survival analysis, patients who refused enucleation were censored and those with non-
215 evaluable HRPF or HS and one who developed a second tumor were excluded from these
216 analyses.

217

218 **Ethics statements**

219 The HPG Institutional Review Board approved this study (Protocol #979). The study was
220 conducted under the tenets of the Declaration of Helsinki.

221

222 **RESULTS**

223 **Patients characteristics**

224 Clinical and histopathological characteristics are listed in **Table S3** and **Table S4** respectively. Of
225 the 271 enucleated eyes, 181 (66.3%) presented HRPF. All patients who refused eye enucleation
226 at diagnosis and were later enucleated (5/5) had HRPF. In six tumors (2.2%) from patients
227 receiving neoadjuvant therapy, the presence of HRPF was not evaluable due to necrosis greater
228 than 90%.

229

230 **Immunohistochemistry**

231 All tumors included in the study were positive for CRX nuclear staining consistent with the cone
232 origin of human retinoblastoma. ARR3 expression was positive in all eyes in most tumor cells
233 although at different intensities. The strongest expression was found in the most differentiated
234 tumor cells, consistent with ARR3 expression at later stages of the cone cell differentiation
235 process. Expression of TFF1 was cytoplasmic, of heterogeneous intensity and displayed high
236 inter- and intra-tumoral variability.





237 Based on the TFF1 expression, of 273 patients evaluated, 98 (35.9%) were classified as HS1 and
238 162 (59.3%) as HS2. In twenty-two of 273 (8.1%) patients it was not possible to assign a HS by

239 examination of the enucleated eye because of necrosis, but in nine of them it could be assigned
240 by evaluating a biopsy of a metastatic site (**Table S2**). Therefore, 13 (4.8%) patients remain as
241 not evaluable. Examples of each marker immunohistochemistry are presented in **Figure 1A**.
242 Overall, 24 specimens of metastatic sites were available for histological evaluation, 22 (91.7%)
243 were assigned to HS2 and two (8.3%) to HS1 corresponding to one patient whose family refused
244 enucleation and one child with orbital extension at diagnosis who achieved long-term survival
245 (**Figure 1B**).

246 The expression of ARR3 was similar in HS1 (median QS = 200, range 100 to 300) to HS2 (median
247 QS = 200, range 30 to 300) ($P = 0.8953$). The percentage of positive cells for Ki67 was similar in
248 HS1 (median = 75%, range 10% to 95%) compared to tumors classified as HS2 (median = 75%,
249 range 40% to 99%) ($P = 0.3854$) (**Figure 1C**).

250 The TFF1 QS values for tumors that developed metastatic relapse (median = 225, range 100 to
251 300) were significantly higher compared to those of patients with intraocular tumors that did not
252 develop metastasis, including cases with (median = 120, range 0 to 300) or without HRPF (median
253 = 25, range 0 to 300) ($P < 0.0001$). This positive association was not found for ARR3 ($P = 0.8757$)
254 (**Figure 1D**).

255



257 **Figure 1. Immunohistochemical panel expression.** Expression of antibodies included in the
 258 immunohistochemical panel in HS1 and HS2 tumors. (A) HS1 tumors were negative or focally
 259 positive (QS \leq 50) for TFF1 expression, while tumors classified as HS2 were positive (QS > 50)
 260 (Patients RB218 and RB152, respectively). Representative images at panoramic and 4x
 261 magnification. (B) Immunostaining of ARR3 and TFF1 in bone marrow metastasis (patient RB040)
 262 at 4x and 10x magnification. Retinoblastoma cells were positive for both markers. (C) Median
 263 values with interquartile range of QS and percentage of positive cells, obtained for the
 264 differentiation marker ARR3 and Ki67, respectively. Mann-Whitney test was used. (D) TFF1 and
 265 ARR3 QS of patients with intraocular disease at diagnosis included in the initial cohort, grouped
 266 in patients with or without risk factors (HRPF and non-HRPF, respectively) that did not develop
 267 metastasis, and patients that developed metastasis (relapsed). Kruskal-Wallis and Dunn's
 268 multiple comparisons tests were used. ** $P \leq 0.01$ and **** $P \leq 0.0001$.

269

270 **Clinico-pathological correlations**

271 Patients from the initial cohort with intraocular retinoblastoma and HS1 tumors were significantly
 272 younger at diagnosis compared with HS2 tumors. By contrast, children with intraocular disease
 273 at diagnosis and HS2 tumors presented more frequently HRPF in the enucleated eyes, had
 274 significantly higher risk of extraocular relapse and death due to progression of disease compared
 275 to HS1 tumors (**Table 1**).

276

277 **Table 1.** Clinical characteristics of both histological subtype tumors in patients with intraocular
 278 disease included in the initial cohort ($N = 242$).

| | HS1 (N = 96) | HS2 (N = 136) | P value |
|----------------------------------|-------------------------|--------------------------|----------------|
| Gender | | | |
| Male | 55 (57.3%) | 67 (49.3%) | 0.2334 |
| Female | 41 (42.7%) | 69 (50.7%) | |
| Laterality | | | |
| Unilateral | 67 (69.8%) | 106 (77.9%) | 0.1742 |
| Bilateral | 29 (30.2%) | 30 (22.1%) | |
| Age at diagnosis (months) | | | |
| Mean (SD) | 29.0 (31.4) | 30.3 (16.6) | 0.0067 |
| Median [Min, Max] | 16 [0.0, 166.0] | 29.0 [0.0, 85.0] | |

Primary treatment

| | | | |
|---------------------|------------|-------------|--------|
| Enucleation | 78 (81.3%) | 121 (88.9%) | 0.1351 |
| Conservative | 13 (13.5%) | 13 (9.6%) | |
| Neoadjuvant | 2 (2.1%) | 2 (1.5%) | |
| Enucleation refusal | 3 (3.1%) | 0 (0.0%) | |

HRPF

| | | | |
|---------------|------------|-------------|---------|
| Yes | 53 (55.2%) | 103 (75.8%) | < 0.001 |
| No | 43 (44.8%) | 32 (23.5%) | |
| Not evaluable | 0 (0.0%) | 1 (0.7%) | |

Adjuvant therapy

| | | | |
|-----|------------|------------|--------|
| Yes | 51 (53.1%) | 93 (63.4%) | 0.0201 |
| No | 45 (46.9%) | 43 (31.6%) | |

Relapse

| | | | |
|-----|------------|-------------|--------|
| Yes | 3 (3.1%) | 21 (15.4%) | 0.0020 |
| No | 93 (96.9%) | 115 (84.6%) | |

Status

| | | | |
|--------------------|------------|-------------|--------|
| Alive disease free | 93 (96.9%) | 121 (89.0%) | 0.0424 |
| Death | 3 (3.1%) | 14 (10.3%) | |
| Lost to follow up | 0 (0.0%) | 1 (0.7%) | |

279 Ten patients were not evaluable for assigning histological subtype.

280 Wilcoxon test was used to compare the age at diagnosis. Fisher's exact test was used for all other variables.

281 Abbreviations: HS1: histological subtype 1; HS2: histological subtype 2; HRPF: high-risk pathology factors.

282

283 **Extraocular relapse according to histological subtype**




284 Twenty-four patients (24/242, 9.9%) with intraocular disease of the initial cohort had an
 285 extraocular relapse after enucleation. Clinical characteristics of this subgroup are detailed in
 286 **Figure S2.**

287 Overall, in the initial cohort, 228 (90.5%) patients are alive and disease free with a median follow-
 288 up of 62 months (range 2 to 370) and 23 (9.1%) died of disease with a median survival of 15
 289 months (range 1 to 82).

290 Five-year event free survival and OS for patients with HS1 tumors was significantly higher than
 291 compared to patients with HS2 tumors ($P = 0.0003$ and $P = 0.0019$, respectively) (**Figure 2A**).

292 The 5-year EFS using HS classification were 100.0% (95% CI 100.0% to 100.0%) for HS1 and
 293 85.3% (95%CI 79.2% to 91.9%) for HS2, whilst the 5-year OS were 100.0% (95% CI 100.0% to
 294 100.0%) and 88.8% (95% CI 83.2 to 94.8%), respectively. Multivariate Cox analysis showed a

295 significantly higher risk of extraocular relapse and death for patients with HS2, and tumors with
296 postlaminar infiltration of the optic nerve. **Table 2** summarizes the statistical significance of the
297 main variables. All factors evaluated in univariate analysis and their results are listed in **Table S5**
298 and **Table S6**.
299



301 **Figure 2. Histological subtype 2 tumors are associated with higher risk of relapse.** (A)
302 Event-free survival and OS of patients included in the initial cohort with intraocular disease at
303 diagnosis stratified according to the histological subtype classification. (B) Representative images
304 for expression of ARR3 and TFF1 in mutually and non-mutually exclusive expression patterns
305 (Patient RB098 and RB011 respectively) at panoramic and 2x magnification. Histological subtype
306 2 tumors display intratumoral heterogeneity, with areas ARR3+/TFF1- intertwined with ARR3-
307 /TFF1+ regions ($N = 57$) or ARR3+/TFF1+ in all tumor cells ($N = 60$). (C) Event-free and overall
308 survival of patients included in the initial cohort with intraocular disease and HS2, classified
309 according to the presence or absence of the dual expression pattern.
310
311 **Table 2.** Cox proportional hazards regression models in retinoblastoma patients for association
312 of retinoblastoma features and histological subtypes classification with probability of event-free
313 survival and overall survival.

| Variable | Univariate analysis | | | Multivariate analysis | | |
|-----------------------------|----------------------|----------|----------------|-----------------------|----------|----------------|
| | HR [95% CI] | P-value | Global P-value | HR [95% CI] | P-value | Global P-value |
| Event free survival | | | | | | |
| Histological subtype | | | | | | |
| HS1 | Ref | | | | | |
| HS2 | 28.50 [3.92;3626.36] | < 0.0001 | - | 33.08 [4.38;4238.50] | < 0.0001 | - |
| Optic nerve invasion | | | | | | |
| No | Ref | | | Ref | | |
| Prelaminar | 0.39 [0.08;1.93] | 0.25 | 0.0036 | 0.33 [0.06;1.30] | 0.12 | 0.0024 |
| Intralaminar | 0.52 [0.06;4.29] | 0.54 | | 0.35 [0.04;1.66] | 0.20 | |
| Postlaminar | 0.43 [0.13;1.42] | 0.17 | | 0.25 [0.08;0.79] | 0.019 | |
| Resection margin | 6.07 [1.84;20.00] | 0.0031 | | 2.83 [0.86;8.97] | 0.085 | |
| Overall survival | | | | | | |
| Histological subtype | | | | | | |
| HS1 | Ref | | | Ref | | |
| HS2 | 20.45 [2.74;2613.57] | 0.00054 | - | 26.88 [3.44;3465.72] | 0.00020 | - |
| Optic nerve invasion | | | | | | |
| No | Ref | | | Ref | | |
| Prelaminar | 0.29 [0.03;2.59] | 0.27 | 0.00041 | 0.22 [0.02;1.29] | 0.095 | 0.0013 |
| Intralaminar | 0.82 [0.09;7.32] | 0.86 | | 0.55 [0.05;2.97] | 0.51 | |
| Postlaminar | 0.36 [0.08;1.63] | 0.19 | | 0.19 [0.04;0.82] | 0.026 | |
| Resection margin | 10.4 [2.76;39.00] | 0.00054 | | 3.36 [0.78;13.97] | 0.010 | |
| Sclera invasion | | | | | | |
| No | Ref | | | Ref | | |
| Intrascleral | 1.41 [0.37;5.30] | 0.61 | 0.026 | 1.04 [0.25;3.43] | 0.95 | 0.14 |
| Transcleral | 9.44 [2.50;35.70] | 0.00093 | | 4.87 [0.99;20.61] | 0.051 | |

315

316 Abbreviations: CI: confidence interval; HR: hazard risk; HS1: Histological subtype 1; HS2: Histological
317 subtype 2. Ref: reference. An event was defined as extraocular relapse.

318

319 **Risk factors for extraocular relapse in HS2**

320 Since all cases with extraocular relapse (except those that occurred in patients whose families
321 declined enucleation) occurred in HS2, we analyzed this cohort separately to further screen for
322 those with the highest risk of relapse. As previously reported for EBF3 (another marker for subtype
323 2 tumors)⁹, we found two different patterns of expression of TFF1 and ARR3: (i) a non-mutually
324 exclusive expression characterized by the expression of ARR3 and TFF1 (ARR3+/TFF1+) in all
325 tumor cells, shown in 44.1% (60/136) of samples; and (ii) a mutually exclusive expression pattern
326 whereby areas of ARR3+/TFF1- cells were alternated with regions ARR3-/TFF1+ seen in 41.9%
327 (57/136) of cases. In the mutually exclusive pattern, the ARR3+/TFF1- area corresponded to well-
328 differentiated tumor cells with the presence of rosettes in 77.2% (44/57) of cases (**Figure 2B**). In
329 13.9% (18/136) of samples the dual pattern of expression could not be determined, and these
330 cases were excluded from the analysis.

331 Patients with HS2 tumors with a mutually exclusive expression were significantly younger at
332 diagnosis compared to patients with the non-mutually exclusive expression pattern (median 24.5
333 months, range 0 to 85 vs 32.5 months, range 1 to 82 respectively; $P = 0.0035$). The non-mutually
334 exclusive expression pattern was associated with a higher risk of relapse and death of disease
335 compared to tumors with the mutually exclusive expression pattern ARR3+/TFF1- or ARR3-
336 /TFF1+ ($P = 0.0010$ and $P = 0.0017$, respectively) (**Figure 2C**). The 5-year EFS and OS were
337 96.5% (95% CI 91.8% to 100.0%) and 97.4% (95% CI 92.4% to 100.0%) for HS2 mutually
338 exclusive expression tumors, and 72.6% (CI 95% 61.0% to 86.0%) and 78.1% (95% CI 67.4% to
339 90.6%) for HS2 non-mutually exclusive expression pattern, respectively.

340 In the multivariate analysis performed in HS2 tumors from the initial cohort, the non-mutually
341 exclusive expression pattern was the only statistically significant predictor of EFS, whilst together
342 with postlaminar invasion of the optic nerve remained significant in the OS analysis (**Table 3**). All
343 studied factors included in the univariate analysis are shown in **Table S7** and **Table S8**.

344

345

346 **Table 3.** Cox proportional hazards regression models in retinoblastoma patients for association of HS2 tumors with different pattern of expression
 347 with probability of event-free survival and overall survival.

348

| Variable | Univariate analysis | | | Multivariate analysis | | |
|--------------------------------------|---------------------|---------|----------------|-----------------------|---------|----------------|
| | HR [95% CI] | P-value | Global P-value | HR [95% CI] | P-value | Global P-value |
| Event free survival | | | | | | |
| Mutually exclusive expression | | | | | | |
| No | Ref | | | Ref | | |
| Yes | 0.12 [0.03;0.54] | 0.0057 | - | 0.14 [0.03;0.65] | 0.012 | - |
| Optic nerve invasion | | | | | | |
| No | Ref | | | Ref | | |
| Prelaminar | 0.41 [0.07;2.23] | 0.30 | 0.034 | 0.50 [0.09;2.73] | 0.42 | 0.10 |
| Intralaminar | 0.43 [0.05;3.84] | 0.45 | | 0.60 [0.07;5.44] | 0.65 | |
| Postlaminar | 0.28 [0.07;1.04] | 0.057 | | 0.28 [0.08;1.07] | 0.062 | |
| Resection margin | 2.60 [0.65;10.40] | 0.18 | | 1.80 [0.45;7.28] | 0.41 | |
| Overall survival | | | | | | |
| Mutually exclusive expression | | | | | | |
| No | Ref | | | Ref | | |
| Yes | 0.08 [0.01;0.61] | 0.015 | - | 0.10 [0.01;0.76] | 0.027 | - |
| Optic nerve invasion | | | | | | |
| No | Ref | | | Ref | | |
| Prelaminar | 0.26 [0.03;2.50] | 0.24 | 0.0047 | 0.32 [0.03;3.05] | 0.32 | 0.013 |
| Intralaminar | 0.65 [0.07;6.25] | 0.71 | | 0.77 [0.08;7.49] | 0.82 | |
| Postlaminar | 0.20 [0.04;0.99] | 0.049 | | 0.20 [0.04;0.98] | 0.047 | |
| Resection margin | 4.11 [0.91;18.50] | 0.066 | | 2.85 [0.63;12.93] | 0.18 | |

349 Abbreviations: HPG: Hospital JP Garrahan; HSJD: Hospital Sant Joan de Déu; QS: Quick score. Ref: reference

350 DISCUSSION

351 Our results in a large patient cohort, show the feasibility and clinical relevance of an
352 immunohistochemical panel as a surrogate of the recently reported retinoblastoma molecular
353 subtypes. We provide additional characterization of patients with HS2 tumors presenting more
354 commonly with HRPF, older age, higher likelihood of metastatic dissemination at diagnosis and
355 statistically significant higher risk of metastatic relapse and death of disease. Furthermore, we
356 found a higher-risk subgroup among patients with HS2 tumors, identifiable by the presence of a
357 non-mutually exclusive histopathological expression of TFF1 and ARR3. Because
358 immunohistochemistry is available at relatively low cost in many centers treating retinoblastoma
359 worldwide, it would be feasible in clinical scenarios with limited resources for genomic studies.

360 TFF1 was selected for our study based on its high expression in subtype 2 retinoblastoma in a
361 multi-omic study and its role as a biomarker in retinoblastoma has recently been proposed⁹. Other
362 investigators had previously described a relationship of TFF1 expression with higher TNM clinical
363 stage²¹ and as predictive marker of advanced stage in aqueous humor biopsies¹⁵.

364 Many studies have tried to identify biological risk factors in retinoblastoma, but most correlated
365 putative factors with the presence of HRPF and not to actual occurrence of extraocular relapse
366 and/or death²². Although nearly all patients who develop an extraocular relapse have HRPF, more
367 than 90% of the patients with HRPF do not relapse and many even without other treatment than
368 enucleation. Therefore, the correlation of any biological feature with the presence of HRPF has
369 a low probability to identify the true high-risk patient who is the one with a high-risk for extraocular
370 relapse despite standard treatment and is therefore at risk of dying.

371 Our data show a significant difference in EFS and OS between patients with TFF1 positive *versus*
372 negative immunohistochemical staining. This information may be helpful for taking future clinical
373 decisions since the risk of extraocular relapse for patients with HS1 was limited to those declining
374 timely enucleation, regardless of HRPF. All patients with intraocular HS1 retinoblastoma achieved
375 long-term survival, indicating that de-escalation of therapy is likely to be safe in these patients.
376 This is in line with the reported observation that subtype 1 tumors show a stable genome with
377 very few genomic events besides *RB1* alterations⁹. Since subtype 1 is more common in patients
378 with germline *RB1* mutations, the avoidance of adjuvant therapy in these patients is critical to

379 prevent long-term chemo and radiotherapy side effects that including potentially fatal treatment-
380 related secondary malignancies²³.

381 All cases presenting with metastatic disease and all those with extraocular relapse (refusal of
382 enucleation excluded) had HS2 tumors, which may be justified by their higher genomic instability
383 and presence of additional chromosomal alterations and mutations. Our data showed a
384 significantly higher expression of TFF1 when intraocular cases with no HRPF were compared to
385 those with HRPF and when those with HRPF with no metastasis are compared to those who
386 developed metastasis. However, it was not possible to find a cut-off value for assigning a very
387 high-risk group based only on TFF1 expression and QS was not associated independently to poor
388 prognosis in multivariate analysis. Notably, within the cohort of patients with HS2 tumors, we show
389 that the non-exclusive expression pattern of ARR3/TFF1 was an additional risk factor in the
390 multivariate analysis.

391 Based on our data, we would suggest that patients with HS2 and HRPF, especially if a non-
392 mutually exclusive pattern is detected are at higher risk of extraocular relapse and should receive
393 adjuvant treatment. In cases with non-mutually exclusive pattern of ARR3/TFF1, a higher intensity
394 adjuvant therapy may be considered in future studies. Genomic studies to detect additional
395 chromosomal abnormalities such as gains in 1p, 17q and 19q, losses of 11q and mutations in
396 *BCOR* and *MYCN* gains/amplification may provide additional information for further risk
397 stratification. Studies of minimal residual disease or more recently, liquid biopsy may also
398 contribute to describe a very high-risk group warranting intensive treatment²⁴⁻²⁷.

399 Some limitations to our work need to be acknowledged. This study was done on archival
400 specimens over a long period of time and only limited number of slides were available for some
401 cases. In addition, patients received treatment across successive studies and the efficacy of
402 adjuvant therapy may alter the prognostic significance of TFF1 expression. The additional use of
403 other markers such as EBF3, as reported by Liu et al.⁹, or molecular studies may provide
404 additional information. In our series, germline *RB1* mutations were not studied systematically in
405 our cohort, therefore patients with heritable unilateral retinoblastoma may have been missed if no
406 family history was present. Finally, despite the large number of patients included in the study the
407 number of events was relatively low. Prospective validation of these immunohistochemistry
408 criteria together with other biological parameters in multicentric prospective studies are needed

409 for their use in standard treatment. In cases where adjuvant therapy is debated (for instance
410 isolated choroidal invasion or even retrolaminar optic nerve invasion) it could be discussed to
411 incorporate this subtypes classification as a one more factor in favor of the need or withdrawal of
412 adjuvant treatment.

413

414 **CONCLUSIONS**

415 TFF1 expression detected by immunohistochemistry as a surrogate for subtype 2 tumors,
416 especially when it presents with a non-mutually exclusive pattern with ARR3, is a new prognostic
417 factor independently associated to higher risk of extraocular relapse and death in patients with
418 retinoblastoma and HRPF.

419

420 **REFERENCES**

- 421 1. All WCf. [https://cdn.who.int/media/docs/default-source/documents/health-](https://cdn.who.int/media/docs/default-source/documents/health-topics/cancer/cureall-framework-who-global-initiative-for-childhood-cancer-pamphlet.pdf?sfvrsn=6e9c5b1b_8)
422 [topics/cancer/cureall-framework-who-global-initiative-for-childhood-cancer-](https://cdn.who.int/media/docs/default-source/documents/health-topics/cancer/cureall-framework-who-global-initiative-for-childhood-cancer-pamphlet.pdf?sfvrsn=6e9c5b1b_8)
423 [pamphlet.pdf?sfvrsn=6e9c5b1b_8](https://cdn.who.int/media/docs/default-source/documents/health-topics/cancer/cureall-framework-who-global-initiative-for-childhood-cancer-pamphlet.pdf?sfvrsn=6e9c5b1b_8)
- 424 2. Munier FL, Beck-Popovic M, Chantada GL, et al. Conservative management of
425 retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive,
426 with good vision and no comorbidity". *Prog Retin Eye Res*. Nov 2019;73:100764.
427 doi:10.1016/j.preteyeres.2019.05.005
- 428 3. Sullivan EM, Wilson MW, Billups CA, et al. Pathologic risk-based adjuvant chemotherapy
429 for unilateral retinoblastoma following enucleation. *J Pediatr Hematol Oncol*. Aug
430 2014;36(6):e335-40. doi:10.1097/MPH.000000000000141
- 431 4. Chantada GL, de Davila MT, Fandino A, et al. Retinoblastoma with low risk for extraocular
432 relapse. *Ophthalmic Genet*. Sep 1999;20(3):133-40. doi:10.1076/opge.20.3.133.2277
- 433 5. Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high
434 risk ocular pathological features: who needs adjuvant therapy? *Br J Ophthalmol*. Aug
435 2004;88(8):1069-73. doi:10.1136/bjo.2003.037044
- 436 6. Kaliki S, Tahiliani P, Mishra DK, Srinivasan V, Ali MH, Reddy VA. OPTIC NERVE
437 INFILTRATION BY RETINOBLASTOMA: Predictive Clinical Features and Outcome. *Retina*. Jun
438 2016;36(6):1177-83. doi:10.1097/IAE.0000000000000861

- 439 7. Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on
440 the postoperative treatment of unilateral retinoblastoma after primary enucleation. *J Clin Oncol.*
441 Apr 10 2013;31(11):1458-63. doi:10.1200/JCO.2012.42.3962
- 442 8. Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma:
443 a 13-year experience. *Cancer.* Sep 15 2003;98(6):1292-8. doi:10.1002/cncr.11647
- 444 9. Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness
445 features, dedifferentiated cone states and neuronal/ganglion cell gene expression. *Nat Commun.*
446 Sep 22 2021;12(1):5578. doi:10.1038/s41467-021-25792-0
- 447 10. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic
448 and epigenetic analyses. *Nature.* Jan 11 2012;481(7381):329-34. doi:10.1038/nature10733
- 449 11. Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma
450 staging system. *Pediatr Blood Cancer.* Nov 2006;47(6):801-5. doi:10.1002/pbc.20606
- 451 12. Perez V, Sampor C, Rey G, et al. Treatment of Nonmetastatic Unilateral Retinoblastoma
452 in Children. *JAMA Ophthalmol.* Jul 1 2018;136(7):747-752.
453 doi:10.1001/jamaophthalmol.2018.1501
- 454 13. Ashwin C, Mallapatna BLG, Patricia Chévez-Barrios, Livia Lumbroso-Le Rouic, Guillermo
455 L. Chantada, François Doz, Hervé J. Brisse, Francis L. Munier, Daniel M. Albert, Jaume Català-
456 Mora, Laurence Desjardins, Shigenobu Suzuki, William L. Carroll, Sara E. Coupland and Paul T.
457 Finger. Retinoblastoma. In: Mahul B. Amin SBE, Frederick L. Greene, David R. Byrd, Robert K.
458 Brookland, Mary Kay Washington, Jeffrey E. Gershenwald, Carolyn C. Compton, Kenneth R.
459 Hess, Daniel C. Sullivan, J. Milburn Jessup, James D. Brierley, Lauri E. Gaspar, Richard L.
460 Schilsky, Charles M. Balch, David P. Winchester, Elliot A. Asare, Martin Madera, Donna M. Gress,
461 Laura R. Meyer, ed. *AJCC Cancer Staging Manual.* Springer Cham; 2017:819-831.
- 462 14. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the
463 International Retinoblastoma Staging Working Group on the pathology guidelines for the
464 examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. *Arch*
465 *Pathol Lab Med.* Aug 2009;133(8):1199-202. doi:10.1043/1543-2165-133.8.1199
466 10.5858/133.8.1199

- 467 15. Busch MA, Haase A, Miroschnikov N, et al. TFF1 in Aqueous Humor-A Potential New
468 Biomarker for Retinoblastoma. *Cancers (Basel)*. Jan 28
469 2022;14(3)doi:10.3390/cancers14030677
- 470 16. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *Journal of*
471 *the American Statistical Association*. 1958;53(282):457-481. doi:10.2307/2281868
- 472 17. Kalbfleisch JD, Prentice RL. *The statistical analysis of failure time data*. 2nd ed. ed. Wiley
473 series in probability and statistics. J. Wiley; 2002.
- 474 18. Cox DR. Regression Models and Life-Tables. [https://doi.org/10.1111/j.2517-](https://doi.org/10.1111/j.2517-6161.1972.tb00899.x)
475 [6161.1972.tb00899.x](https://doi.org/10.1111/j.2517-6161.1972.tb00899.x). *Journal of the Royal Statistical Society: Series B (Methodological)*.
476 1972/01/01 1972;34(2):187-202. doi:<https://doi.org/10.1111/j.2517-6161.1972.tb00899.x>
- 477 19. Heinze G, Schemper M. A Solution to the Problem of Monotone Likelihood in Cox
478 Regression. *Biometrics*. 2001;57(1):114-119.
- 479 20. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation
480 Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-
481 Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. *J Mol Diagn*. May
482 2015;17(3):251-64. doi:10.1016/j.jmoldx.2014.12.006
- 483 21. Busch M, Metz K, Beier M, Biewald E, Dunker N. Trefoil Factor Family 1 Expression
484 Correlates with Clinical Outcome in Patients with Retinoblastoma. *Retina*. Dec 2018;38(12):2422-
485 2428. doi:10.1097/IAE.0000000000001881
- 486 22. Ganesan B, Parameswaran S, Sharma A, Krishnakumar S. Clinical relevance of B7H3
487 expression in retinoblastoma. *Sci Rep*. Jun 23 2020;10(1):10185. doi:10.1038/s41598-020-
488 67101-7
- 489 23. Villanueva G, Sampor C, Moreno F, et al. Subsequent malignant neoplasms in the
490 pediatric age in retinoblastoma survivors in Argentina. *Pediatr Blood Cancer*. Aug
491 2022;69(8):e29710. doi:10.1002/pbc.29710
- 492 24. Abramson DH, Mandelker D, Francis JH, et al. Retrospective Evaluation of Somatic
493 Alterations in Cell-Free DNA from Blood in Retinoblastoma. *Ophthalmology Science*.
494 2021;1(1):100015. doi:10.1016/j.xops.2021.100015
- 495 25. Laurent VE, Torbidoni AV, Sampor C, et al. Minimal Disseminated Disease in
496 Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With

497 Disease-Free Survival. *JAMA Ophthalmol.* Dec 1 2016;134(12):1374-1379.
498 doi:10.1001/jamaophthalmol.2016.4158

499 26. Torbidoni AV, Laurent VE, Sampor C, et al. Association of Cone-Rod Homeobox
500 Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. *JAMA*
501 *Ophthalmol.* Jul 2015;133(7):805-12. doi:10.1001/jamaophthalmol.2015.0900

502 27. Cuadrado-Vilanova M, Burgueño V, Balaguer-Lluna L, et al. Follow-up of intraocular
503 retinoblastoma through the quantitative analysis of conserved nuclear DNA sequences in
504 aqueous humor from patients. <https://doi.org/10.1002/cjp2.296>. *The Journal of Pathology: Clinical*
505 *Research.* 2023/01/01 2023;9(1):32-43. doi:<https://doi.org/10.1002/cjp2.296>

506

507 **AUTHOR CONTRIBUTIONS**

508 **Conceptualization**, R.A, F.R, P.S, F.L, G.C; **Data curation**, D.G and S.P.J; **Formal analysis**:
509 R.A, D.G and S.P.J; **Funding acquisition**, P.S and G.C; **Investigation**, R.A, G.L, C.R.P, D.O,
510 S.Z, S.C, E.N, M.C.V, G.P.P, C.S, N.G, B.S, M.S, A.M.C; **Methodology**, R.A, D.G, S.P.J; S.C,
511 E.N; **Project administration**, G.C; **Resources**, A.M.C, F.R, D.H.A, P.S, F.L and G.C; **Software**,
512 D.G, S.P.J; **Supervision**, G.C; **Visualization**, R.A, D.G, G.L and S.P.J; **Writing—original draft**
513 **preparation**, R.A and G.C; **Writing—review and editing**, A.M.C, J.M, M.T.G.D, F.D, F.R, D.H.A,
514 A.S.L, P.S and G.C;

515 All authors have read and agreed to the published version of the manuscript.